Company / Depreciation & Amortization
VYNE Therapeutics Inc. Depreciation & Amortization History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$4.0K
FY2025
5-year range
$0 / $341.0K
FY2021-FY2025
Trend
-
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Depreciation & Amortization returned to growth in FY2025 after 3 years of decline, reaching $4,000.
Based on SEC 10-K filings.
$4,000 in FY2025 with a 5-year CAGR of -58.3%.
Improved from $72,000 to $4,000 over the past 2 years.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- -66.8%
- 5-Year CAGR
- -58.3%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -58.3%, indicating a declining trend.
- Peak depreciation & amortization was recorded in FY2021.
- Lowest depreciation & amortization in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.19 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $4.0K | - |
| FY2024 | $0 | -100.0% |
| FY2023 | $72.0K | -33.9% |
| FY2022 | $109.0K | -68.0% |
| FY2021 | $341.0K | +6.9% |
| FY2020 | $319.0K | - |
| FY2019 | - | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026